 |
0 Diseases |  |
3 Trials |
|
3 Trials |  |
114 News |  |
| «12 |
- || ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Trial completion date, Trial primary completion date, Metastases: SGNLVA-005: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors (clinicaltrials.gov) - Oct 7, 2020
P2, N=264, Recruiting, Sponsor: Seattle Genetics, Inc.
Trial completion date: Jan 2023 --> Jul 2023 | Trial primary completion date: Jul 2021 --> Aug 2022
- ladiratuzumab vedotin (SGN-LIV1A) / Seagen, Merck (MSD)
[VIRTUAL] Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL (Channel 1) - Oct 2, 2020 - Abstract #SABCS2020SABCS_1165;
SGN-LIV1A delivered every 3 weeks was comparable to paclitaxel for the primary endpoint of pCR in I-SPY2 and may have a similar side effect profile, however, with less peripheral neuropathy. Clinical trials evaluating weekly dosing of SGN-LIV1A are ongoing.
- ladiratuzumab vedotin (SGN-LIV1A) / Seattle Genetics, Merck (MSD)
[VIRTUAL] SGNLVA-001: A phase 1 open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer () - Oct 2, 2020 - Abstract #SABCS2020SABCS_1081;
P1
Primary safety endpoint is the incidence of adverse events and dose-limiting toxicities. Key efficacy endpoints include confirmed overall response rate, duration of response, and progression-free survival.
- || ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Trial completion date, Trial primary completion date, Metastases: KEYNOTE 721: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Sep 19, 2020
P1b/2, N=122, Recruiting, Sponsor: Seattle Genetics, Inc.
Key efficacy endpoints include confirmed overall response rate, duration of response, and progression-free survival. Trial completion date: Mar 2023 --> Jun 2023 | Trial primary completion date: Dec 2020 --> Aug 2021
- [VIRTUAL] Combination Immunotherapy (IT) and Chemotherapy (CT) Can Improve Pathologic Complete Responses (pCR) in Women with Triple Negative (TNBC) and HER2+ Breast Cancer (BC) but Does Not Improve Predictability for Post Therapy Magnetic Resonance Imaging (MRI) (ePoster Gallery) - Sep 1, 2020 - Abstract #SSO2020SSO_507;
We analyzed 44 TNBC and HER2 NAICT pts from 4 distinct Trx protocols including: (1) 14 TNBC pts treated with intratumoral Talimogene laherparepvec (TVEC) in combination with weekly paclitaxel (T) followed by dose dense Adriamycin and Cytoxan (ddAC); (2) 13 ER+HER2+ pts treated with subcutaneous interferon gamma (IFN-) in combination with weekly T with trastuzumab and pertuzumab (HP); (3), 6 ER-HER2+ pts treated with 3 weeks of HER2 pulsed dendritic cell vaccines (DC1) followed by Taxotere, Carboplatin, and HP; and (4), 11 pts on ISPY2 trial; 8 pts randomized to Trx with pembrolizumab with weekly T followed by ddAC, 1 pt treated with SGN-LIV1A followed by ddAC, and 2 pts treated with durvalumab, and T, followed by ddAC. The addition of IT with standard CT regimens in TNBC and HER2 BC has improved pCR but reduced the predictive capacity of MRI suggesting MRI may not be accurate enough to make further surgical decisions.
- Keytruda (pembrolizumab) / Merck (MSD), ladiratuzumab vedotin (SGN-LIV1A) / Seattle Genetics, Merck (MSD)
[VIRTUAL] SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_675;
Legal entity responsible for the study: Seattle Genetics/Merck. Funding: Seattle Genetics/Merck.
- || Trial completion date, Trial primary completion date: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Jul 8, 2020
P1/2, N=280, Recruiting, Sponsor: Hoffmann-La Roche
Funding: Seattle Genetics/Merck. Trial completion date: May 2023 --> Jan 2023 | Trial primary completion date: May 2023 --> Jan 2023
- ||||| ladiratuzumab vedotin (SGN-LIV1A) / Seattle Genetics
Clinical, Video: #ASCO20 video: WATCH Jame Abraham @jamecancerdoc (@ClevelandClinic) describe the phase 1 study design for the LIV-1-targeted antibody–drug conjugate ladiratuzumab vedotin in patients with metastatic #BreastCancer #BCSM https://t.co/62zfKWjugV (Twitter) - May 30, 2020
- The Utility of MRI in Predicting Response of Lymph Nodes in HER2-positive and Triple-negative Breast Cancer to Combination Neoadjuvant Immunotherapy and Chemotherapy (NAICT) and Its Implications on Axillary Surgical Management () - May 29, 2020 - Abstract #ASBrS2020ASBrS_225;
NAICT does not interfere with accuracy of MRI in assessment of node-negative disease. The accuracy and sensitivity of MRI increases with greater nodal burden.
- ladiratuzumab vedotin (SGN-LIV1A) / Seattle Genetics
[VIRTUAL] SGNLVA-005: Open-label, phase 2 study of ladiratuzumab vedotin (LV) for aerodigestive tract malignancies () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_376;
P2
Legal entity responsible for the study Seattle Genetics, Inc. Funding Seattle Genetics, Inc.
- || ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Trial completion date, Trial primary completion date, Metastases: SGNLVA-005: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors (clinicaltrials.gov) - May 6, 2020
P2, N=264, Recruiting, Sponsor: Seattle Genetics, Inc.
Funding Seattle Genetics, Inc. Trial completion date: Apr 2021 --> Jan 2023 | Trial primary completion date: Nov 2020 --> Jul 2021
- || Trial completion date, Trial primary completion date: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - May 6, 2020
P1/2, N=280, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Apr 2021 --> Jan 2023 | Trial primary completion date: Nov 2020 --> Jul 2021 Trial completion date: Jun 2022 --> May 2023 | Trial primary completion date: Jun 2022 --> May 2023
- ladiratuzumab vedotin (SGN-LIV1A) / Seattle Genetics
[VIRTUAL] SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer. (Poster Board 189) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1826;
P1
Key efficacy endpoints include confirmed overall response rate, duration of response, and progression-free survival. Research Funding: Seattle Genetics Inc.
- ||| ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Enrollment change, Metastases: SGNLVA-005: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors (clinicaltrials.gov) - Apr 24, 2020
P2, N=264, Recruiting, Sponsor: Seattle Genetics, Inc.
Research Funding: Seattle Genetics Inc. N=180 --> 264
- || Trial completion date, Trial primary completion date: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Apr 10, 2020
P1/2, N=280, Recruiting, Sponsor: Hoffmann-La Roche
N=180 --> 264 Trial completion date: Aug 2021 --> Jun 2022 | Trial primary completion date: Aug 2021 --> Jun 2022
- || ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Trial completion date, Trial primary completion date, Metastases: KEYNOTE 721: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Apr 3, 2020
P1b/2, N=122, Recruiting, Sponsor: Seattle Genetics, Inc.
Trial completion date: Aug 2021 --> Jun 2022 | Trial primary completion date: Aug 2021 --> Jun 2022 Trial completion date: May 2022 --> Mar 2023 | Trial primary completion date: May 2020 --> Dec 2020
- || Keytruda (pembrolizumab) / Merck (MSD), ladiratuzumab vedotin (SGN-LIV1A) / Seagen, Merck (MSD)
Clinical, P1/2 data, Journal, Combination therapy: SGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer. (Pubmed Central) - Feb 23, 2020
Trial completion date: May 2022 --> Mar 2023 | Trial primary completion date: May 2020 --> Dec 2020 No abstract available
- ladiratuzumab vedotin (SGN-LIV1A) / Seattle Genetics
SGNLVA-005: Open-Label, Phase 2 Study of Ladiratuzumab Vedotin (LV) for Advanced Lung Malignancies (Hall 1) - Feb 15, 2020 - Abstract #ELCC2020ELCC_436;
- | Biomarker, Enrollment change, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Feb 10, 2020
P2, N=4000, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
No abstract available N=1920 --> 4000
- || sacituzumab govitecan (IMMU-132) / Immunomedics, ladiratuzumab vedotin (SGN-LIV1A) / Seattle Genetics
.@BurrisSkip discusses the design of sacituzumab govitecan and ladiratuzumab vedotin https://t.co/MhQjvJKaZR (Twitter) - Jan 24, 2020
- | Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Jan 22, 2020
P2, N=1920, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
N=1920 --> 4000 Trial primary completion date: Dec 2020 --> Dec 2025
- | ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Trial completion date, Metastases: SGNLVA-005: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors (clinicaltrials.gov) - Jan 18, 2020
P2, N=180, Recruiting, Sponsor: Seattle Genetics, Inc.
Trial primary completion date: Dec 2020 --> Dec 2025 Trial completion date: Nov 2020 --> Apr 2021
- ladiratuzumab vedotin (SGN-LIV1A) / Seattle Genetics
Sgnlva-005: Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced aerodigestive tract malignancies. (Level 1, West Hall - Poster Board L13) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_447;
P2
Clinical trial information: NCT04032704. Research Funding: Seattle Genetics, Inc
- || ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Trial completion date, Trial primary completion date: SGNLVA-001: A Safety Study of SGN-LIV1A in Breast Cancer Patients (clinicaltrials.gov) - Nov 25, 2019
P1, N=418, Recruiting, Sponsor: Seattle Genetics, Inc.
Research Funding: Seattle Genetics, Inc Trial completion date: Oct 2021 --> Mar 2022 | Trial primary completion date: Nov 2020 --> Apr 2021
- | ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Enrollment open, Metastases: SGNLVA-005: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors (clinicaltrials.gov) - Sep 26, 2019
P2, N=180, Recruiting, Sponsor: Seattle Genetics, Inc.
Trial completion date: Oct 2021 --> Mar 2022 | Trial primary completion date: Nov 2020 --> Apr 2021 Not yet recruiting --> Recruiting
- Keytruda (pembrolizumab) / Merck (MSD), ladiratuzumab vedotin (SGN-LIV1A) / Seattle Genetics
Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer (Hemisfair Ballroom - 3rd Level) - Sep 25, 2019 - Abstract #SABCS2019SABCS_855;
P1b/2
Conclusion LV + pembro appears tolerable with a manageable safety profile to date. Preliminary efficacy data show encouraging clinical activity as first-line therapy in pts with unresectable LA/M TNBC.
- | ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Trial completion date, Trial primary completion date: SGNLVA-001: A Safety Study of SGN-LIV1A in Breast Cancer Patients (clinicaltrials.gov) - Aug 28, 2019
P1, N=378, Recruiting, Sponsor: Seattle Genetics, Inc.
Preliminary efficacy data show encouraging clinical activity as first-line therapy in pts with unresectable LA/M TNBC. Trial completion date: Jun 2021 --> Oct 2021 | Trial primary completion date: Jul 2020 --> Nov 2020
- | ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
New P2 trial, Metastases: SGNLVA-005: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors (clinicaltrials.gov) - Jul 24, 2019
P2, N=180, Not yet recruiting, Sponsor: Seattle Genetics, Inc.
- ||| ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Enrollment change, Metastases: KEYNOTE 721: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Jun 27, 2019
P1b/2, N=97, Recruiting, Sponsor: Seattle Genetics, Inc.
Trial completion date: Jun 2021 --> Oct 2021 | Trial primary completion date: Jul 2020 --> Nov 2020 N=72 --> 97
- | sacituzumab govitecan (IMMU-132) / Immunomedics, glembatumumab vedotin (CDX-011) / Celldex, ladiratuzumab vedotin (SGN-LIV1A) / Seattle Genetics
Journal, BRCA Biomarker: Antibody-drug conjugates in triple negative breast cancer. (Pubmed Central) - Apr 3, 2019
One emerging treatment modality includes antibody-drug conjugates which are highly selective monoclonal antibodies conjugated to cytotoxic agents, designed to deliver cytotoxic drugs to antigen-expressing tumor cells. This review will highlight three antibody-drug conjugates currently being evaluated in TNBC (CDX-011, SGN-LIV1a, IMMU-132), including one that has been given Breakthrough Therapy designation from the US FDA.
- || ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Trial completion date, Trial primary completion date: SGNLVA-001: A Safety Study of SGN-LIV1A in Breast Cancer Patients (clinicaltrials.gov) - Mar 7, 2019
P1, N=366, Recruiting, Sponsor: Seattle Genetics, Inc.
This review will highlight three antibody-drug conjugates currently being evaluated in TNBC (CDX-011, SGN-LIV1a, IMMU-132), including one that has been given Breakthrough Therapy designation from the US FDA. Trial completion date: Jul 2020 --> Jun 2021 | Trial primary completion date: Jul 2019 --> Jul 2020
- | ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Trial completion date, Metastases: KEYNOTE 721: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Mar 7, 2019
P1b/2, N=72, Recruiting, Sponsor: Seattle Genetics, Inc.
Trial completion date: Jul 2020 --> Jun 2021 | Trial primary completion date: Jul 2019 --> Jul 2020 Trial completion date: May 2020 --> May 2022
- || ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Enrollment change, Trial completion date, Trial primary completion date: SGNLVA-001: A Safety Study of SGN-LIV1A in Breast Cancer Patients (clinicaltrials.gov) - Mar 12, 2018
P1, N=306, Recruiting, Sponsor: Seattle Genetics, Inc.
Trial completion date: May 2020 --> May 2022 N=216 --> 306 | Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: Dec 2018 --> Jul 2019
- |||| ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Enrollment open, Trial initiation date, Metastases: KEYNOTE 721: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Mar 5, 2018
P1b/2, N=72, Recruiting, Sponsor: Seattle Genetics, Inc.
N=216 --> 306 | Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: Dec 2018 --> Jul 2019 Not yet recruiting --> Recruiting | Initiation date: Mar 2018 --> Feb 2018
- ||| ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Trial initiation date, Metastases: KEYNOTE 721: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Mar 3, 2018
P1b/2, N=72, Not yet recruiting, Sponsor: Seattle Genetics, Inc.
Not yet recruiting --> Recruiting | Initiation date: Mar 2018 --> Feb 2018 Initiation date: Jan 2018 --> Mar 2018
- |||| Enrollment open, Trial initiation date: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Mar 2, 2018
P1/2, N=260, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Jan 2018 --> Mar 2018 Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Mar 2018
- ||||| New P1/2 trial: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Feb 5, 2018
P1/2, N=260, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Oct 20, 2017
P2, N=1920, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Mar 2018 Trial primary completion date: Dec 2018 --> Dec 2020
- || ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Trial primary completion date: SGNLVA-001: A Safety Study of SGN-LIV1A in Breast Cancer Patients (clinicaltrials.gov) - Jul 31, 2017
P1, N=216, Recruiting, Sponsor: Seattle Genetics, Inc.
Trial primary completion date: Dec 2018 --> Dec 2020 Trial primary completion date: Feb 2018 --> Dec 2018
- Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Dec 7, 2016
P2, N=1920, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Trial primary completion date: Feb 2018 --> Dec 2018 Trial primary completion date: May 2018 --> Dec 2018
- || ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Enrollment change: SGNLVA-001: A Safety Study of SGN-LIV1A in Breast Cancer Patients (clinicaltrials.gov) - Jul 29, 2016
P1, N=216, Recruiting, Sponsor: Seattle Genetics, Inc.
Trial primary completion date: May 2018 --> Dec 2018 N=81 --> 216
- Biomarker, Enrollment change, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Jul 13, 2016
P2, N=1920, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
N=81 --> 216 N=1200 --> 1920 | Trial primary completion date: Sep 2017 --> May 2018
- || ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Enrollment change, Trial primary completion date: SGNLVA-001: A Safety Study of SGN-LIV1A in Breast Cancer Patients (clinicaltrials.gov) - May 10, 2016
P1, N=81, Recruiting, Sponsor: Seattle Genetics, Inc.
N=1200 --> 1920 | Trial primary completion date: Sep 2017 --> May 2018 N=66 --> 81 | Trial primary completion date: Apr 2016 --> Feb 2018
- || ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Trial primary completion date: SGNLVA-001: A Safety Study of SGN-LIV1A in Breast Cancer Patients (clinicaltrials.gov) - Dec 4, 2015
P1, N=66, Recruiting, Sponsor: Seattle Genetics, Inc.
N=66 --> 81 | Trial primary completion date: Apr 2016 --> Feb 2018 Trial primary completion date: Oct 2015 --> Apr 2016
- Biomarker, Enrollment change, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=1200, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Trial primary completion date: Oct 2015 --> Apr 2016 N=800 --> 1200 | Trial primary completion date: Sep 2015 --> Sep 2017
- Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Sep 22, 2014
P2, N=800, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
N=800 --> 1200 | Trial primary completion date: Sep 2015 --> Sep 2017 Trial primary completion date: Feb 2014 --> Sep 2015
- || ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Enrollment change: SGNLVA-001: A Safety Study of SGN-LIV1A in Breast Cancer Patients (clinicaltrials.gov) - Aug 15, 2014
P1, N=66, Recruiting, Sponsor: Seattle Genetics, Inc.
Trial primary completion date: Feb 2014 --> Sep 2015 N=51 --> 66
- ||| ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
New P1 trial: SGNLVA-001: A Safety Study of SGN-LIV1A in Breast Cancer Patients (clinicaltrials.gov) - Oct 23, 2013
P1, N=51, Recruiting, Sponsor: Seattle Genetics, Inc.
- ||| ladiratuzumab vedotin (SGN-LIV1A) / Merck (MSD), Pfizer
Enrollment open: SGNLVA-001: A Safety Study of SGN-LIV1A in Breast Cancer Patients (clinicaltrials.gov) - Oct 20, 2013
P1, N=51, Recruiting, Sponsor: Seattle Genetics, Inc.
N=51 --> 66 Not yet recruiting --> Recruiting